Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPA objects to liquid supplement guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA may violate the Administrative Procedures Act by apparently changing enforcement discretion policy regarding liquid dietary supplement products, according to the Natural Products Association. FDA's stance in a December 2009 draft guidance that some liquid products labeled as supplements may be conventional beverages should be promulgated through notice-and-comment rulemaking, NPA VP of Scientific & Regulatory Affairs Daniel Fabricant says in a Feb. 2 1letter. NPA asks FDA as it finalizes the guidance to say why it rejects or accepts comments. The trade group adds the guidance lacks "a verifiable or scientific standard" to delineate supplement and conventional food packaging - a point other stakeholders make (2"The Tan Sheet" Feb. 8, 2010)

You may also be interested in...



FDA Should Not Judge A Liquid Supplement By Its Packaging - Stakeholders

An FDA guidance document conflicts with the Dietary Supplement Health and Education Act and agency precedent by questioning the classification of liquid products labeled as supplements, according to industry comments

China Detains Legend Biotech CEO, Exposes Genetic Material Minefield

Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.

QUOTED. 23 September 2020. US FDA

Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel